Gsa Capital Partners LLP Denali Therapeutics Inc. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$20.63 - $30.17 $771,644 - $1.13 Million	37,404 New	37,404 $771,000
Q2 2022 Aug 09, 2022	SELL	$20.88 - $35.19 $144,907 - $244,218	-6,940 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$29.0 - $47.27 $32,074 - $52,280	1,106 Added 18.96%	6,940 $223,000
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $385,780 - $498,371	-9,058 Reduced 60.82%	5,834 $260,000
Q3 2021 Nov 12, 2021	BUY	$48.48 - $78.23 $721,964 - $1.17 Million	14,892 New	14,892 $751,000
Q2 2021 Aug 05, 2021	SELL	$50.3 - $78.44 $280,824 - $437,930	-5,583 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$53.8 - $81.53 $300,365 - $455,181	5,583 New	5,583 $319,000
Q3 2019 Nov 12, 2019	SELL	$15.32 - $21.92 $391,640 - $560,362	-25,564 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$18.5 - $28.14 $300,514 - $457,106	16,244 Added 174.29%	25,564 $531,000
Q1 2019 May 15, 2019	BUY	$17.99 - $24.65 $167,666 - $229,738	9,320 New	9,320 $216,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.